- Home
- NTHI vs MEIP Comparison
NTHI vs MEIP Comparison
Compare NTHI & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTHI
- MEIP
- Stock Information
- Founded
- NTHI 2008
- MEIP 2000
- Country
- NTHI United States
- MEIP United States
- Employees
- NTHI N/A
- MEIP N/A
- Industry
- NTHI Biotechnology: Pharmaceutical Preparations
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- NTHI Health Care
- MEIP Health Care
- Exchange
- NTHI Nasdaq
- MEIP Nasdaq
- Market Cap
- NTHI 155.4M
- MEIP 153.9M
- IPO Year
- NTHI N/A
- MEIP 2003
- Fundamental
- Price
- NTHI $9.88
- MEIP $3.07
- Analyst Decision
- NTHI
- MEIP
- Analyst Count
- NTHI 0
- MEIP 0
- Target Price
- NTHI N/A
- MEIP N/A
- AVG Volume (30 Days)
- NTHI 72.4K
- MEIP 1.2M
- Earning Date
- NTHI 08-19-2025
- MEIP 09-23-2025
- Dividend Yield
- NTHI N/A
- MEIP N/A
- EPS Growth
- NTHI N/A
- MEIP N/A
- EPS
- NTHI N/A
- MEIP N/A
- Revenue
- NTHI $59,990.00
- MEIP N/A
- Revenue This Year
- NTHI N/A
- MEIP N/A
- Revenue Next Year
- NTHI N/A
- MEIP N/A
- P/E Ratio
- NTHI N/A
- MEIP N/A
- Revenue Growth
- NTHI N/A
- MEIP 33.76
- 52 Week Low
- NTHI $3.20
- MEIP $1.46
- 52 Week High
- NTHI $25.00
- MEIP $9.00
- Technical
- Relative Strength Index (RSI)
- NTHI N/A
- MEIP 30.71
- Support Level
- NTHI N/A
- MEIP $2.76
- Resistance Level
- NTHI N/A
- MEIP $5.50
- Average True Range (ATR)
- NTHI 0.00
- MEIP 0.39
- MACD
- NTHI 0.00
- MEIP -0.26
- Stochastic Oscillator
- NTHI 0.00
- MEIP 11.31
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.